Global Health (OTCBB: GHLV) Begins Manufacturing of X-Excite in Europe

Global Health Ventures Inc. (OTCBB: GHLV) recently announced that it has signed an agreement with Pharmex Rom Industries SRL of Bucharest to manufacture X-Excite drug under GMP protocol. Pharmex is a contract manufacturer of pharmaceutical drugs for human use. Pharmex is a certified GMP (Good Manufacturing Practice) under the European Regulatory Guidance (EMEA) and Japanese Regulatory guidance. Under the terms of the agreement Pharmex shall manufacture X-Excite for clinical trials in Europe and other countries that recognize European Regulatory Authority's approval.

MicroCap Insider is a web-based financial portal.

Sign Up for our Free Stock Newsletter

MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.

"We have chosen a strategy to first develop our drugs in Europe, as a large number of countries recognize European Regulatory Approval and the cost of development to the Company is lower than FDA Approval. We have however planned to carry out the trials under the FDA guidance after the European approval," said Dr. Hassan Salari, Global Health President and CEO. X-Excite is a male sexual enhancement drug. It is a new formulation of an existing sexual enhancement drug, which is designed to rapidly enter the blood system, maximizing its efficacy and performance. The drug is developed to work sublingually, thus having a more rapid mode of action, and bypassing all the inconveniences and many side effects associated with other application routs. It is expected that the market for such products may continue to grow and the Company hopes to capture a sizable portion of this market.

Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.

About Us

MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.

Please click here to read the full disclaimer.